FRAXA Research Foundation is dedicated to funding breakthrough research, providing $240,000 to reactivate the FMR1 gene to combat Fragile X Syndrome, with the goal of restoring vital protein function and advancing towards a cure.
Read moredemethylation
Innovative Breakthrough in Fragile X Treatment: The Promise of Antisense Oligonucleotide (ASO) Therapy
![Innovative Breakthrough in Fragile X Treatment: The Promise of Antisense Oligonucleotide (ASO) Therapy](https://www.fraxa.org/wp-content/uploads/2023/06/Richter-Shah-Berry-Kravis-Watts-Banbury-Meeting-720x300.jpg)
This changes everything! FRAXA funded research introduces Antisense Oligonucleotide (ASO) Therapy, redefining Fragile X syndrome treatment and understanding.
Read moreReactivating the FMR1 Gene
![Reactivating the FMR1 Gene Andre Hoogeveen , PhD](https://www.fraxa.org/wp-content/uploads/2004/07/hoogeveen-andre.jpg)
With a $171,600 grant from FRAXA Research Foundation from 1998-2004, Dr. Andre Hoogeveen and his team at Erasmus University researched methods to reactivate the Fragile X gene.
Read moreTransgenic Mouse Model Studies of Fragile X Syndrome
![Transgenic Mouse Model Studies of Fragile X Syndrome Dr. Eric Kandel, MD, Columbia University, FRAXA research grant](https://www.fraxa.org/wp-content/uploads/2013/05/Kandel-Eric.jpg)
With a $410,000 grant from FRAXA Research Foundation from 1999-2001, Dr. Eric Kandel and his team at Columbia University researched development of Fragile X mice to further aid future studies of Fragile X research.
Read more